10-Q: NeurAxis Reports Strong Revenue Growth in Q2 2026

NeurAxis, Inc. announced a significant increase in net sales and gross profit for the second quarter of 2026, driven by expanded insurance coverage for its IB-Stim device.

Summary

• NeurAxis, Inc. reported substantial revenue growth for the three and six months ended June 30, 2026, with net sales increasing by 115.7% and 97.6% respectively, compared to the prior year periods.
• Gross profit also saw significant increases, rising by 121.6% for the three-month period and 102.6% for the six-month period.
• Gross margin improved to 85.9% for the quarter and 86.1% for the six months, up from 83.6% and 84.0% respectively.
• Despite revenue growth, the company continued to incur operating losses, with a net loss of $2,085,746 for the three months and $3,847,178 for the six months ended June 30, 2026.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• Cash and cash equivalents increased to $8,322,258 as of June 30, 2026, and the company has a working capital surplus of $6,317,762.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic score, reflecting significant revenue growth and improved gross margins, but tempered by continued operating losses and going concern doubts.

Positives

• Net sales increased by 115.7% to $1,928,695 for the three months ended June 30, 2026, and by 97.6% to $3,536,578 for the six months ended June 30, 2026.
• Gross profit increased by 121.6% to $1,656,122 for the three months and 102.6% to $3,045,639 for the six months.
• Gross margin improved to 85.9% for the quarter and 86.1% for the six months.
• Cash and cash equivalents increased to $8,322,258 as of June 30, 2026.
• Working capital surplus increased to $6,317,762 as of June 30, 2026.
• The company's IB-Stim device received a Category I CPT code effective January 1, 2026, leading to broader insurance coverage.
• The average selling price increased due to more sales to patients with full reimbursement.

Negatives

• The company incurred a net loss of $2,085,746 for the three months and $3,847,178 for the six months ended June 30, 2026.
• Operating loss increased by 23.7% to $2,124,712 for the three months ended June 30, 2026.
• Auditors have expressed substantial doubt about the company's ability to continue as a going concern.
• General and administrative expenses increased by 45.6% for the three-month period, primarily due to stock compensation and market access costs.
• The company has a history of incurring significant operating losses since inception.
• The company may never achieve profitability.

Risks

• The company's ability to continue as a going concern is dependent on its ability to generate sufficient revenues and raise additional funds through public or private offerings.
• The company has incurred losses and negative cash flows from operations since inception.
• Future capital requirements depend on developing, manufacturing, and marketing technologies, patent costs, establishing collaborations, and market developments.
• The company's success relies on achieving widespread insurance coverage for its IB-Stim and RED devices.
• There are material weaknesses in the company's internal control over financial reporting, including ineffective approval processes, inadequate contract management, and misapplication of U.S. GAAP.
• Dr. Arturo Taca has asserted an interest in a patent and is seeking approximately $2,000,000 in compensation, which the company disputes.

Future Outlook

The company expects to incur significant expenses and operating losses for the foreseeable future as it pursues widespread insurance coverage for its devices and seeks FDA clearance for additional indications. Future capital requirements are substantial and depend on various factors including R&D progress, market adoption, and regulatory approvals. The company intends to fund future operations through additional financing.

Management Comments

• Our mission is to advance drug-free neuromodulation therapies that improve patient outcomes and reduce medication burden in complex disorders, while expanding access to effective care for populations with significant unmet needs.
• Although we had stockholders equity of $6,735,053 as of June 30, 2026, our auditors have expressed substantial doubt about our ability to continue as a going concern.
• We expect to incur significant expenses and operating losses for the foreseeable future as we continue to pursue widespread insurance coverage of our IB-Stim and RED devices and seek FDA clearance of our device for other indications.
• The primary activity that will drive all customers and revenues is the adoption of insurance coverage by commercial insurance carriers nationally, which is a top priority of the Company.

Industry Context

StockSavvy.ai notes that NeurAxis operates in the growing medical neuromodulation device market, focusing on pediatric chronic pain conditions. The company's recent revenue surge is directly linked to securing a Category I CPT code, a critical step for reimbursement and market penetration, which is a common pathway for medical device adoption.

Comparison to Industry Standards

• The company's gross margin of approximately 86% is strong, potentially exceeding industry averages for medical device manufacturers, especially those in early commercialization stages.
• However, the continued operating losses and the auditor's going concern opinion are significant concerns, indicating challenges in scaling operations profitably, a common hurdle for many early-stage medical technology companies.
• Competitors in the neuromodulation space, such as companies developing spinal cord stimulators or deep brain stimulators, often face lengthy R&D cycles and significant regulatory hurdles, similar to NeurAxis's pursuit of additional FDA indications.

Corporate Governance

Legal Proceedings

• A lawsuit initiated in 2019 by Ritu Bhambhani, M.D. and Sudhir Rao against Innovative Health Solutions, Inc. and others, asserting claims under the RICO Act and related to Medicare/insurance reimbursement of the NeuroStim device, was dismissed and affirmed on appeal.
• A subsequent lawsuit initiated in 2022 by related entities owned by the same plaintiffs against the Company and others, asserting similar claims, resulted in dismissal of RICO claims and a settlement reached on April 25, 2025, for $750,000, payable in installments, with $375,000 remaining as of June 30, 2026.
• Dr. Arturo Taca asserted an interest in U.S. Patent No. 10,413,719 and sought compensation of approximately $2,000,000; the Company disputes these claims and intends to defend vigorously.

Related Party Transactions

• Demand notes receivable from shareholders totaling $1,012,800 with fully reserved principal and interest.
• Interest payable to certain shareholders related to convertible notes totaling $66,648.
• Exclusive license for the auricular portion of certain patents owned by an LLC in which the CEO and Chief Regulatory Officer have ownership interest, with pre-approved reimbursement of up to $20,000 for license costs.
• Board of Directors members purchase NeuroStim devices at cost for research, with pre-approved sales up to $20,000 for the year.

Stakeholder Impact

• Shareholders: Continued operating losses and going concern doubts may impact stock value, while revenue growth and potential future profitability offer upside.
• Employees: Stock-based compensation is a significant expense, and the company is actively granting RSUs and ESPP opportunities.
• Creditors: The company's ability to meet its obligations is subject to its success in raising capital and generating revenue.
• Customers (Healthcare Providers): Increased insurance coverage for IB-Stim is a positive development, facilitating adoption.

Next Steps

• Continue to pursue widespread insurance coverage for IB-Stim and RED devices.
• Seek FDA clearance for additional indications for the IB-Stim device, including post-concussion syndrome, cyclic vomiting syndrome, post-operative pain, and fibromyalgia pain.
• Continue remediation efforts for material weaknesses in internal control over financial reporting.
• Implement planned research and development efforts requiring significant working capital.

Key Dates

Recommendation

The significant revenue growth and improved gross margins are positive indicators, suggesting market traction for the IB-Stim device due to expanded insurance coverage. However, the persistent operating losses, substantial doubt about the company's ability to continue as a going concern, and material weaknesses in internal controls present considerable risks. While the growth trajectory is encouraging, the path to profitability remains uncertain, warranting a 'hold' position until these fundamental financial and operational challenges are demonstrably resolved.

Keywords

neuromodulation devices, IB-Stim, functional abdominal pain, irritable bowel syndrome, functional dyspepsia, medical devices, FDA clearance, insurance coverage